WASHINGTON (AP) -- Federal health regulators have halted Amgen's (NASDAQ: AMGN) studies of its thyroid drug Sensipar after the death of a 14-year-old patient in a company trial.
The Food and Drug Administration said Tuesday it is still gathering information about the death, but has shut down all studies of the drug in children.
Sensipar is approved in adults to treat over-activity of the parathyroid gland. It has been used since 2004 to treat symptoms of chronic kidney disease and parathyroid cancer.
Amgen Inc. had been studying the drug to see whether it works in children.
The Thousand Oaks, Calif.-based company said in a statement that it "is working as rapidly as possible to understand the circumstances of what happened."
The FDA said on its website that it is unclear whether Amgen's drug had a role in the patient's death, but it is reminding doctors to prescribe it carefully.
The drug is known to lower calcium levels, sometimes to a dangerous extent.
The agency says doctors should monitor patients' calcium levels monthly to make sure they don't fall to dangerous levels. Signs of a calcium deficiency include muscle cramping, convulsions and burning or prickling sensations.
The most common side effects of the drug in adults include nausea, vomiting and diarrhea.
Amgen shares fell 7 cents to $89.48 in afternoon trading Tuesday.
The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.